Jun 28, 2019

Proceedings from a CME symposium held at the 2019 ASCO Annual Meeting. Featuring perspectives from Prof Fabrice André and Drs Virginia Kaklamani, Mark D Pegram, Hope S Rugo, Sara M Tolaney and Tiffany A Traina:

• Introduction
  • Program overview: Dr Love (00:00)
• Available and Emerging Data Sets Shaping the Management of Localized HER2-Positive Breast Cancer (BC)
  • Case (Dr Rugo): A woman in her mid-40s with ER/PR-negative, HER2-positive BC who received neoadjuvant TCHP and experienced a pathologic complete response (3:57)
  • Case (Dr Rugo): A woman in her mid-50s with an ER-positive, HER2-positive infiltrating lobular carcinoma who received neoadjuvant chemotherapy/anti-HER2 therapy, had residual disease at surgery and initiated treatment with T-DM1 (6:39)
  • Case (Dr Rugo): A woman in her early 40s with an ER-positive, HER2-positive IDC who received postadjuvant neratinib (11:42)
  • Faculty Presentation: Dr Rugo (14:18)
• Use of Genomic Classifiers in Clinical Decision-Making for Patients with ER-Positive Early BC
  • Case (Dr Kaklamani): A postmenopausal woman in her late 50s with an ER/PR-positive, HER2-negative, node-negative IDC and a 21-gene Recurrence Score^® of 24 (38:46)
  • Case (Dr Kaklamani): A postmenopausal woman in her mid-50s with an ER/PR-positive, HER2-negative IDC with 2 positive nodes and a 21-gene Recurrence Score of 21 (41:47)
  • Faculty Presentation: Dr Kaklamani (48:39)
• Selection and Sequence of Therapy for ER-Positive, HER2-Negative Metastatic BC (mBC); Novel Agents and Strategies Under Evaluation in ER-Positive Disease
  • Case (Prof André): A postmenopausal woman in her mid-50s who presented with ER/PR-positive, HER2-negative mBC approximately 2 years after the completion of adjuvant letrozole (1:07:13)
  • Case (Prof André): A woman in her mid-70s with de novo ER/PR-positive, HER2-negative mBC with extensive liver involvement who received palbociclib/letrozole (1:10:03)
  • Faculty Presentation: Prof André (1:11:05)
• Immunotherapy as a Rational Therapeutic Strategy in BC
  • Case (Dr Tolaney): A woman in her early 60s with metastatic triple-negative BC (TNBC) who received atezolizumab/nab paclitaxel and remains NED 4 years later (1:28:14)
  • Case (Dr Tolaney): A woman in her mid-60s with heavily pretreated TNBC who experienced a complete response to pembrolizumab but developed treatment-related diabetes and hypothyroidism (1:31:00)
  • Faculty Presentation: Dr Tolaney (1:32:49)
• Protocol and Off-Protocol Decision-Making for Patients with HER2-Positive mBC
  • Case (Dr Pegram): A woman in her mid-60s with widespread ER-negative, HER2-positive mBC who received tucatinib/capecitabine/trastuzumab on a clinical trial (1:46:01)
  • Faculty Presentation: Dr Pegram (1:47:28)
• Role of PARP Inhibitors, Novel Agents in mBC; Male Breast Cancer
  • Case (Dr Traina): A woman in her early 60s with metastatic TNBC and a germline BRCA2 mutation who received olaparib monotherapy and achieved a complete response (2:11:31)
  • Case (Dr Traina): A woman in her early 70s with metastatic androgen receptor-positive TNBC who received an investigational antiandrogen on a clinical trial (2:13:12)
  • Case (Dr Traina): A man in his early 60s with ER/PR-positive, HER2-negative mBC and a germline BRCA2 mutation (2:16:16)
  • Faculty Presentation: Dr Traina (2:18:32)

Select publications